StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Depreciation, amortisation & impairment added back in by Quarter

Depreciation, amortisation & impairment added back in EBITDA ($M) ($M)

QuarterlyAnnual

AstraZeneca Depreciation, amortisation & impairment added back in: $1,928M in Q2 2026, up 38.8% from a year earlier.

Latest, Q2 2026
1,928
Period ended Jun 30, 2026
Change on a year earlier
+38.8%
1,389 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| Depreciation, amortisation and impairment | 3,295 | | 2,673 | 23 | 21 | | | 1,928 | 1,389 | | 39 | | 38”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F EBITDA Reconciliation Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDepreciation, amortisation & impairment added back in EBITDA ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20261,928+38.8%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 20261,366+6.4%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 20251,511-35.3%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 20251,549-14.7%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 20251,389+8.6%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 20251,284+2.3%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 20242,337+76.1%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 20241,817+41.7%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 20241,279+0.2%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 20241,255-16.4%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 20231,327-10.3%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 20231,282-3.9%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 20231,276-6.0%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 20231,502+14.7%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 20221,480-32.5%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 20221,334-52.2%Form 6-K FY2022Q3 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Depreciation, amortisation & impairment added back in ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ebitda-da-impairment

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.